Zai Lab Initiates Global Phase 2 Clinical Trial of Topical 1L-17 Blocker in Chronic Plaque Psoriasis
The first patient has been dosed in Zai Lab’s global Phase 2 clinical trial of ZL-1102, a topical anti-IL-17 investigational therapy for the treatment of mild to moderate chronic plaque psoriasis. ZL-1102 is a novel human VH antibody fragment (Humabody), targeting the IL-17A cytokine, formulated as a hydrogel for topical use in the treatment of […]